Outcome following treatment of feline gastrointestinal mast cell tumours

L. E. Barrett, Katherine A Skorupski, D. C. Brown, N. Weinstein, C. Clifford, A. Szivek, S. Haney, S. Kraiza, E. L. Krick

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prognosis of feline gastrointestinal mast cell tumours (FGIMCT), based on limited available literature, is described as guarded to poor, which may influence treatment recommendations and patient outcome. The purpose of this study is to describe the clinical findings, treatment response, and outcome of FGIMCT. Medical records of 31 cats diagnosed with and treated for FGIMCT were retrospectively reviewed. Data collected included signalment, method of diagnosis, tumour location (including metastatic sites), treatment type, cause of death and survival time. Mean age was 12.9y. Diagnosis was made via cytology (n=15), histopathology (n=13) or both (n=3). Metastatic sites included abdominal lymph node (n=10), abdominal viscera (n=4) and both (n=2). Therapeutic approaches included chemotherapy alone (n=15), surgery and chemotherapy (n=7), glucocorticoid only (n=6) and surgery and glucocorticoid (n=3). Lomustine (n=15) and chlorambucil (n=12) were the most commonly used chemotherapy drugs. Overall median survival time was 531d (95% confidence interval 334, 982). Gastrointestinal location, diagnosis of additional cancers, and treatment type did not significantly affect survival time. Cause of death was tumour-related or unknown (n=12) and unrelated (n=8) in the 20 cats dead at the time of analysis. The prognosis for cats with FGIMCT may be better than previously reported, with 26% of cats deceased from an unrelated cause. Surgical and medical treatments (including prednisolone alone) were both associated with prolonged survival times. Treatment other than prednisolone may not be necessary in some cats. Continued research into prognostic factors and most effective treatment strategies are needed.

Original languageEnglish (US)
JournalVeterinary and Comparative Oncology
DOIs
StateAccepted/In press - 2017

Fingerprint

Felidae
mast cells
Mast Cells
cats
neoplasms
Cats
Neoplasms
Survival
drug therapy
Prednisolone
Drug Therapy
prednisolone
Therapeutics
Glucocorticoids
Cause of Death
glucocorticoids
prognosis
Lomustine
Chlorambucil
surgery

Keywords

  • Chemotherapy
  • Feline intestinal neoplasms
  • Mast cell tumours
  • Surgery

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Barrett, L. E., Skorupski, K. A., Brown, D. C., Weinstein, N., Clifford, C., Szivek, A., ... Krick, E. L. (Accepted/In press). Outcome following treatment of feline gastrointestinal mast cell tumours. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12326

Outcome following treatment of feline gastrointestinal mast cell tumours. / Barrett, L. E.; Skorupski, Katherine A; Brown, D. C.; Weinstein, N.; Clifford, C.; Szivek, A.; Haney, S.; Kraiza, S.; Krick, E. L.

In: Veterinary and Comparative Oncology, 2017.

Research output: Contribution to journalArticle

Barrett, LE, Skorupski, KA, Brown, DC, Weinstein, N, Clifford, C, Szivek, A, Haney, S, Kraiza, S & Krick, EL 2017, 'Outcome following treatment of feline gastrointestinal mast cell tumours', Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12326
Barrett, L. E. ; Skorupski, Katherine A ; Brown, D. C. ; Weinstein, N. ; Clifford, C. ; Szivek, A. ; Haney, S. ; Kraiza, S. ; Krick, E. L. / Outcome following treatment of feline gastrointestinal mast cell tumours. In: Veterinary and Comparative Oncology. 2017.
@article{5c36cc7914624b0884a4f2346dfb742e,
title = "Outcome following treatment of feline gastrointestinal mast cell tumours",
abstract = "Prognosis of feline gastrointestinal mast cell tumours (FGIMCT), based on limited available literature, is described as guarded to poor, which may influence treatment recommendations and patient outcome. The purpose of this study is to describe the clinical findings, treatment response, and outcome of FGIMCT. Medical records of 31 cats diagnosed with and treated for FGIMCT were retrospectively reviewed. Data collected included signalment, method of diagnosis, tumour location (including metastatic sites), treatment type, cause of death and survival time. Mean age was 12.9y. Diagnosis was made via cytology (n=15), histopathology (n=13) or both (n=3). Metastatic sites included abdominal lymph node (n=10), abdominal viscera (n=4) and both (n=2). Therapeutic approaches included chemotherapy alone (n=15), surgery and chemotherapy (n=7), glucocorticoid only (n=6) and surgery and glucocorticoid (n=3). Lomustine (n=15) and chlorambucil (n=12) were the most commonly used chemotherapy drugs. Overall median survival time was 531d (95{\%} confidence interval 334, 982). Gastrointestinal location, diagnosis of additional cancers, and treatment type did not significantly affect survival time. Cause of death was tumour-related or unknown (n=12) and unrelated (n=8) in the 20 cats dead at the time of analysis. The prognosis for cats with FGIMCT may be better than previously reported, with 26{\%} of cats deceased from an unrelated cause. Surgical and medical treatments (including prednisolone alone) were both associated with prolonged survival times. Treatment other than prednisolone may not be necessary in some cats. Continued research into prognostic factors and most effective treatment strategies are needed.",
keywords = "Chemotherapy, Feline intestinal neoplasms, Mast cell tumours, Surgery",
author = "Barrett, {L. E.} and Skorupski, {Katherine A} and Brown, {D. C.} and N. Weinstein and C. Clifford and A. Szivek and S. Haney and S. Kraiza and Krick, {E. L.}",
year = "2017",
doi = "10.1111/vco.12326",
language = "English (US)",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Outcome following treatment of feline gastrointestinal mast cell tumours

AU - Barrett, L. E.

AU - Skorupski, Katherine A

AU - Brown, D. C.

AU - Weinstein, N.

AU - Clifford, C.

AU - Szivek, A.

AU - Haney, S.

AU - Kraiza, S.

AU - Krick, E. L.

PY - 2017

Y1 - 2017

N2 - Prognosis of feline gastrointestinal mast cell tumours (FGIMCT), based on limited available literature, is described as guarded to poor, which may influence treatment recommendations and patient outcome. The purpose of this study is to describe the clinical findings, treatment response, and outcome of FGIMCT. Medical records of 31 cats diagnosed with and treated for FGIMCT were retrospectively reviewed. Data collected included signalment, method of diagnosis, tumour location (including metastatic sites), treatment type, cause of death and survival time. Mean age was 12.9y. Diagnosis was made via cytology (n=15), histopathology (n=13) or both (n=3). Metastatic sites included abdominal lymph node (n=10), abdominal viscera (n=4) and both (n=2). Therapeutic approaches included chemotherapy alone (n=15), surgery and chemotherapy (n=7), glucocorticoid only (n=6) and surgery and glucocorticoid (n=3). Lomustine (n=15) and chlorambucil (n=12) were the most commonly used chemotherapy drugs. Overall median survival time was 531d (95% confidence interval 334, 982). Gastrointestinal location, diagnosis of additional cancers, and treatment type did not significantly affect survival time. Cause of death was tumour-related or unknown (n=12) and unrelated (n=8) in the 20 cats dead at the time of analysis. The prognosis for cats with FGIMCT may be better than previously reported, with 26% of cats deceased from an unrelated cause. Surgical and medical treatments (including prednisolone alone) were both associated with prolonged survival times. Treatment other than prednisolone may not be necessary in some cats. Continued research into prognostic factors and most effective treatment strategies are needed.

AB - Prognosis of feline gastrointestinal mast cell tumours (FGIMCT), based on limited available literature, is described as guarded to poor, which may influence treatment recommendations and patient outcome. The purpose of this study is to describe the clinical findings, treatment response, and outcome of FGIMCT. Medical records of 31 cats diagnosed with and treated for FGIMCT were retrospectively reviewed. Data collected included signalment, method of diagnosis, tumour location (including metastatic sites), treatment type, cause of death and survival time. Mean age was 12.9y. Diagnosis was made via cytology (n=15), histopathology (n=13) or both (n=3). Metastatic sites included abdominal lymph node (n=10), abdominal viscera (n=4) and both (n=2). Therapeutic approaches included chemotherapy alone (n=15), surgery and chemotherapy (n=7), glucocorticoid only (n=6) and surgery and glucocorticoid (n=3). Lomustine (n=15) and chlorambucil (n=12) were the most commonly used chemotherapy drugs. Overall median survival time was 531d (95% confidence interval 334, 982). Gastrointestinal location, diagnosis of additional cancers, and treatment type did not significantly affect survival time. Cause of death was tumour-related or unknown (n=12) and unrelated (n=8) in the 20 cats dead at the time of analysis. The prognosis for cats with FGIMCT may be better than previously reported, with 26% of cats deceased from an unrelated cause. Surgical and medical treatments (including prednisolone alone) were both associated with prolonged survival times. Treatment other than prednisolone may not be necessary in some cats. Continued research into prognostic factors and most effective treatment strategies are needed.

KW - Chemotherapy

KW - Feline intestinal neoplasms

KW - Mast cell tumours

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=85020110771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020110771&partnerID=8YFLogxK

U2 - 10.1111/vco.12326

DO - 10.1111/vco.12326

M3 - Article

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

ER -